Albert David Limited (BOM:524075)
808.85
+1.15 (0.14%)
At close: Aug 17, 2026
Albert David Revenue
Albert David had revenue of 1.01B INR in the quarter ending June 30, 2026, with 43.60% growth. This brings the company's revenue in the last twelve months to 3.64B, up 11.43% year-over-year. In the fiscal year ending March 31, 2026, Albert David had annual revenue of 3.34B, down -3.52%.
Revenue (ttm)
3.64B
Revenue Growth
+11.43%
P/S Ratio
1.27
Revenue / Employee
2.47M
Employees
1,476
Market Cap
4.61B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.34B | -121.70M | -3.52% |
| Mar 31, 2025 | 3.46B | -166.94M | -4.61% |
| Mar 31, 2024 | 3.62B | 208.97M | 6.12% |
| Mar 31, 2023 | 3.42B | 280.53M | 8.95% |
| Mar 31, 2022 | 3.14B | 660.62M | 26.70% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ZIM Laboratories | 3.97B |
| Amanta Healthcare | 2.91B |
| Medico Remedies | 2.38B |
| Kilitch Drugs (India) | 2.38B |
| Medicamen Biotech | 2.06B |
| Ambalal Sarabhai Enterprises | 1.99B |
| Everest Organics | 1.97B |
| Jenburkt Pharmaceuticals | 1.69B |